Navigation Links
Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites
Date:5/12/2010

RESEARCH TRIANGLE PARK, N.C., May 12 /PRNewswire/ -- The International Collaborative Cancer Group, in collaboration with the Institute of Cancer Research Clinical Trials and Statistics Unit, is running the Intergroup Exemestane Study (IES).  IES is a randomized, double blind multinational trial of post menopausal women with early breast cancer and a median follow-up period of 91 months. Max Neeman will be responsible for the compilation of the data from multiple centers.

This landmark trial has the longest follow-up of endocrine treatment in the adjuvant switch setting with approximately 2300 patients from across the globe.  The study evaluates the clinical benefits of switching over to Aromasin after two to three years of Tamoxifen in comparison with patients put on only Tamoxifen for a full, five year period.

Max Neeman provides Data Management/EDC service for large Phase IV multicentric trials to companies across the globe, in 60 countries to date.  Max Neeman also conducts post-marketing observational studies for multiple indications of hypertension, contact dermatitis, acute coronary syndrome, cessation of smoking, renal carcinoma, breast carcinoma, age related macular degeneration and fungal infections.  

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 22 cities with 5 regional offices.  Contact Donald Swankie, Vice President of Business Development, for more information via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Max Neeman International to Open Phase I/IIa Unit
2. China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity
3. Yongye International Announces Conference Call to Discuss First Quarter Fiscal Year 2010 Results
4. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
5. Yongye International to Present at Upcoming Investor Conferences
6. Yongye International, Inc. Begins Construction of New Production Facility
7. Microfluidics International Corporation to Report First Quarter 2010 Financial Results on May 11, 2010
8. Dyadic International Strengthens Management Team
9. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
10. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
11. Frommer Lawrence & Haugs Thomas J. Kowalski Named to the International Whos Who of Patent Attorneys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  Renova™ Therapeutics, a biotechnology company ... and type 2 diabetes, announced that it has ... virus (AAV) vector developed in the laboratory of ... Stanford University. The company plans to use this ... product pipeline. "Early research has ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard ...
(Date:12/8/2016)... 8, 2016  Anaconda BioMed S.L., a pre-clinical stage ... next generation neuro-thrombectomy system for the treatment of Acute ... Jovin, MD to join its Scientific Advisory Board (SAB). ... network of scientific and clinical experts to Anaconda BioMed ... ANCD BRAIN ® to its clinical phase. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...
Breaking Biology Technology:
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016  Zimmer Biomet ... that it has priced an offering of €500.0 million principal ... €500.0 million principal amount of its 2.425% senior unsecured notes ... is expected to occur on December 13, 2016, subject to the ... on an annual basis. ...
(Date:12/2/2016)... Texas , Dec. 1, 2016   ... today announced BioLock , an electrocardiogram (ECG) ... health monitoring, a key IoT asset. The smart ... into a vehicle,s steering wheel and mobile devices ... simple touch. As vehicle technology advances, ...
Breaking Biology News(10 mins):